Variations in reverse transcriptase and RNase H domain mutations in human immunodeficiency virus type 1 clinical isolates are associated with divergent phenotypic resistance to zidovudine

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 11, 2007, Pages 3861-3869

  Ntemgwa, Michel ^a,b   Wainberg, Mark A ^a,b,e   Oliveira, Maureen ^a   Moisi, Daniela ^a   Lalonde, Richard ^c   Micheli, Valeria ^d   Brenner, Bluma G ^a  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^d UNIVERSITY OF MILAN   (Italy)

^e MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

APRICITABINE; BETA 2',3' DIDEHYDRO 2',3' DIDEOXY 5 FLUOROCYTIDINE; BETA DEXTRO 5 FLUORODIOXOLANE CYTOSINE; CYTIDINE; CYTOSINE; RIBONUCLEASE H; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; THYMIDINE DERIVATIVE; UNCLASSIFIED DRUG; ZIDOVUDINE;

AMINO ACID ANALYSIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; GENETIC POLYMORPHISM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; IN VIVO STUDY; MUTATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DOMAIN; VIRUS ISOLATION; VIRUS MUTATION; VIRUS RESISTANCE;

ADENINE; AMINO ACID SEQUENCE; DEOXYCYTIDINE; DRUG RESISTANCE, MULTIPLE, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION; PHENOTYPE; PHOSPHONIC ACIDS; RIBONUCLEASE H; RNA-DIRECTED DNA POLYMERASE; SEQUENCE HOMOLOGY, AMINO ACID; VARIATION (GENETICS); ZIDOVUDINE;

EID: 35848960087     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00646-07     Document Type: Article

References (42)

1. Adachi, A., H. E. Gendelman, S. Koenig, T. Folks, R. Willey, A. Rabson, and M. A. Martin. 1986. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J. Virol. 59:284-291.
2. Akouamba, B. S., J. Viel, H. Charest, N. Merindol, J. Samson, N. Lapointe, B. G. Brenner, R. Lalonde, P. R. Harrigan, M. Boucher, and H. Soudeyns. 2005. HIV-1 genetic diversity in antenatal cohort, Canada. Emerg. Infect. Dis. 11:1230-1234.
3. Bethell, R. C., Y. S. Lie, and N. T. Parkin. 2005. In vitro activity of SPD754, a new deoxycytidine nucleoside reverse transcriptase inhibitor (NRTI), against 215 HIV-1 isolates resistant to other NRTIs. Antivir. Chem. Chemother. 16:295-302.
4. Brehm, J., D. Koontz, V. Pathak, N. Sluis-Cremer, and J. Mellors. 2006. Abstr. 13th Conf. Retrovir. Opportunistic Infect., abstr. 601.
5. Calvez, V., D. Costagliola, D. Descamps, A. Yvon, G. Collin, A. Cecile, C. Delaugerre, F. Damond, A. G. Marcelin, S. Matheron, A. Simon, M. A. Valantin, C. Katlama, and F. Brun-Vezinet. 2002. Impact of stavudine phenotype and thymidine analogues mutations on viral response to stavudine plus lamivudine in ALTIS 2 ANRS trial. Antivir. Ther. 7:211-218.
6. Davies, J. F., II, Z. Hostomska, Z. Hostomsky, S. R. Jordan, and D. A. Matthews. 1991. Crystal structure of the ribonuclease H domain of HIV-1 reverse transcriptase. Science 252:88-95.
7. de Muys, J. M., H. Gourdeau, N. Nguyen-Ba, D. L. Taylor, P. S. Ahmed, T. Mansour, C. Locas, N. Richard, M. A. Weinberg, and R. F. Rando. 1999. Anti-human immunodeficiency virus type 1 activity, intracellular metabolism, and pharmacokinetic evaluation of 2′-deoxy-3′-oxa-4′- thiocytidine. Antimicrob. Agents Chemother. 43:1835-1844.
8. Diallo, K., B. Marchand, X. Wei, L. Cellai, M. Gotte, and M. A. Weinberg. 2003. Diminished RNA primer usage associated with the L74V and M184V mutations in the reverse transcriptase of human immunodeficiency virus type 1 provides a possible mechanism for diminished viral replication capacity. J. Virol. 77:8621-8632.
9. Frankel, F. A., B. Marchand, D. Turner, M. Gotte, and M. A. Wainberg. 2005. Impaired rescue of chain-terminated DNA synthesis associated with the L74V mutation in human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 49:2657-2664.
10. Gotte, M., D. Arion, M. A. Parniak, and M. A. Wainberg. 2000. The M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1 impairs rescue of chain-terminated DNA synthesis. J. Virol. 74:3579-3585.
11. Gu, Z., B. Allard, J. M. de Muys, J. Lippens, R. F. Rando, N. Nguyen-Ba, C. Ren, P. McKenna, D. L. Taylor, and R. C. Bethell. 2006. In vitro antiretroviral activity and in vitro toxicity profile of SPD754, a new deoxycytidine nucleoside reverse transcriptase inhibitor for treatment of human immunodeficiency virus infection. Antimicrob. Agents Chemother. 50:625-631.
12. Hang, J. Q., Y. Yang, Y. Li, S. Tsing, J. Barnett, N. Cammack, and K. Klumpp. 2005. Abstr. 14th Int. HIV Drug Resist. Workshop, abstr. 87.
13. Hanna, G. J., V. A. Johnson, D. R. Kuritzkes, D. D. Richman, A. J. Brown, A. V. Savara, J. D. Hazelwood, and R. T. D'Aquila. 2000. Patterns of resistance mutations selected by treatment of human immunodeficiency virus type 1 infection with zidovudine, didanosine, and nevirapine. J. Infect. Dis. 181:904-911.
14. Johnson, V. A., F. Brun-Vezinet, B. Clotet, D. R. Kuritzkes, D. Pillay, J. M. Schapiro, and D. D. Richman. 2006. Update of the drug resistance mutations in HIV-1: fall 2006. Top. HIV Med. 14:125-130.
15. Julias, J. G., M. J. McWilliams, S. G. Sarafianos, E. Arnold, and S. H. Hughes. 2002. Mutations in the RNase H domain of HIV-1 reverse transcriptase affect the initiation of DNA synthesis and the specificity of RNase H cleavage in vivo. Proc. Natl. Acad. Sci. USA 99:9515-9520.
16. Kellam, P., C. A. Boucher, and B. A. Larder. 1992. Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine. Proc. Natl. Acad. Sci. USA 89:1934-1938.
17. Kuritzkes, D. R., R. L. Bassett, J. D. Hazelwood, H. Barrett, R. A. Rhodes, R. K. Young, and V. A. Johnson. 2004. Rate of thymidine analogue resistance mutation accumulation with zidovudine- or stavudine-based regimens. J. Acquir. Immune Defic. Syndr. 36:600-603.
18. Larder, B. A., G. Darby, and D. D. Richman. 1989. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 243:1731-1734.
19. Lennerstrand, J., K. Hertogs, D. K. Stammers, and B. A. Larder. 2001. Correlation between viral resistance to zidovudine and resistance at the reverse transcriptase level for a panel of human immunodeficiency virus type 1 mutants. J. Virol. 75:7202-7205.
20. Loemba, H., B. Brenner, M. A. Parniak, S. Ma'ayan, B. Spira, D. Moisi, M. Oliveira, M. Detorio, and M. A. Wainberg. 2002. Genetic divergence of human immunodeficiency virus type 1 Ethiopian clade C reverse transcriptase (RT) and rapid development of resistance against nonnucleoside inhibitors of RT. Antimicrob. Agents Chemother. 46:2087-2094.
21. Marcelin, A. G., V. Calvez, and F. Raffi. 2007. Comprehensive guide - HIV resistance to reverse transcriptase nucleoside inhibitors. MediEdition, St. Laurent, Quebec, Canada.
22. Marcelin, A. G., C. Delaugerre, M. Wirden, P. Viegas, A. Simon, C. Katlama, and V. Calvez. 2004. Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure. J. Med. Virol. 72:162-165.
23. Marcelin, A. G., B. Roquebert, I. Malet, M. Wirden, A. Simon, C. Katlama, and V. Calvez. 2005. Abstr. 14th Int. HIV Drug Resist. Workshop, abstr. 88.
24. Miranda, L. R., M. Gotte, F. Liang, and D. R. Kuritzkes. 2005. The L74V mutation in human immunodeficiency virus type 1 reverse transcriptase counteracts enhanced excision of zidovudine monophosphate associated with thymidine analog resistance mutations. Antimicrob. Agents Chemother. 49:2648-2656.
25. Nikolenko, G. N., K. A. Frankenberry, S. Palmer, F. Maldarelli, J. W. Mellors, J. M. Coffin, and V. K. Pathak. 2005. RNase H domains obtained from treatment-experienced patients increase resistance to AZT. Antivir. Ther. 10:S89.
26. Nikolenko, G. N., K. A. Delviks-Frankenberry, S. Palmer, F. Maldarelli, M. J. Fivash, Jr., J. M. Coffin, and V. K. Pathak. 2007. Mutations in the connection domain of HIV-1 reverse transcriptase increase 3′-azido-3′-deoxythymidine resistance. Proc. Natl. Acad. Sci. USA 104:317-322.
27. Nikolenko, G. N., S. Palmer, F. Maldarelli, J. W. Mellors, J. M. Coffin, and V. K. Pathak. 2004. Abstr. 13th Int. HIV Drug Resist. Workshop, abstr. 20.
28. Nikolenko, G. N., S. Palmer, F. Maldarelli, J. W. Mellors, J. M. Coffin, and V. K. Pathak. 2005. Mechanism for nucleoside analog-mediated abrogation of HIV-1 replication: balance between RNase H activity and nucleotide excision. Proc. Natl. Acad. Sci. USA 102:2093-2098.
29. Nikolenko, G. N., E. S. Svarovskaia, K. A. Delviks, and V. K. Pathak. 2004. Antiretroviral drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase increase template-switching frequency. J. Virol. 78:8761-8770.
30. Perno, C. F., V. Svicher, and F. Ceccherini-Silberstein. 2006. Novel drug resistance mutations in HIV: recognition and clinical relevance. AIDS Rev. 8:179-190.
31. Roquebert, B., M. Wirden, A. Simon, J. Deval, C. Katlama, V. Calvez, and A. G. Marcelin. 2007. Relationship between mutations in HIV-1 RNase H domain and nucleoside reverse transcriptase inhibitors resistance mutations in naive and pre-treated HIV infected patients. J. Med. Virol. 79:207-211.
32. Salomon, H., A. Belmonte, K. Nguyen, Z. Gu, M. Gelfand, and M. A. Wainberg. 1994. Comparison of cord blood and peripheral blood mononuclear cells as targets for viral isolation and drug sensitivity studies involving human immunodeficiency virus type 1. J. Clin. Microbiol. 32:2000-2002.
33. Schatz, O., F. V. Cromme, F. Gruninger-Leitch, and S. F. Le Grice. 1989. Point mutations in conserved amino acid residues within the C-terminal domain of HIV-1 reverse transcriptase specifically repress RNase H function. FEBS Lett. 257:311-314.
34. Schinazi, R. F., J. Mellors, H. Bazmi, S. Diamond, S. Garber, K. Gallagher, R. Geleziunas, R. Klabe, M. Pierce, M. Rayner, J. T. Wu, H. Zhang, J. Hammond, L. Bacheler, D. J. Manion, M. J. Otto, L. Stuyver, G. Trainer, D. C. Liotta, and S. Erickson-Viitanen. 2002. DPC 817: a cytidine nucleoside analog with activity against zidovudine- and lamivudine-resistant viral variants. Antimicrob. Agents Chemother. 46:1394-1401.
35. Schinazi, R. F., J. Mellors, S. Erickson-Viitanen, J. Mathew, U. Parikh, P. Sharma, M. Otto, Z. Yang, C. K. Chu, and D. C. Liotta. 2002. Abstr. 11th Int. HIV Drug Resist. Workshop, abstr. 19.
36. Taylor, D. L., P. S. Ahmed, A. S. Tyms, L. J. Wood, L. A. Kelly, P. Chambers, J. Clarke, J. Bedard, T. L. Bowlin, and R. F. Rando. 2000. Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(±)-2′-deoxy-3′-oxa-4′- thiocytidine, dOTC]. Antivir. Chem. Chemother. 11:291-301.
37. Tisdale, M., T. Schulze, B. A. Larder, and K. Moelling. 1991. Mutations within the RNase H domain of human immunodeficiency virus type 1 reverse transcriptase abolish virus infectivity. J. Gen. Virol. 72(Pt 1):59-66.
38. Turner, D., B. Brenner, and M. A. Wainberg. 2004. Relationships among various nucleoside resistance-conferring mutations in the reverse transcriptase of HIV-1. J. Antimicrob. Chemother. 53:53-57.
39. Volkmann, S., B. M. Wohrl, M. Tisdale, and K. Moelling. 1993. Enzymatic analysis of two HIV-1 reverse transcriptase mutants with mutations in carboxyl-terminal amino acid residues conserved among retroviral ribonucleases H. J. Biol. Chem. 268:2674-2683.
40. Wainberg, M. A., B. G. Brenner, and D. Turner. 2005. Changing patterns in the selection of viral mutations among patients receiving nucleoside and nucleotide drug combinations directed against human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 49:1671-1678.
41. Wolf, K., H. Walter, N. Beerenwinkel, W. Keulen, R. Kaiser, D. Hoffmann, T. Lengauer, J. Selbig, A. M. Vandamme, K. Korn, and B. Schmidt. 2003. Tenofovir resistance and resensitization. Antimicrob. Agents Chemother. 47:3478-3484.
42. Yap, S. H., B. Wynhoven, M. Kuiper, C. W. Sheen, N. Sluis-Cremer, R. Harrigan, and G. Tachedjian. 2007. Abstr. 14th Conf. Retrovir. Opportunistic Infect., abstr. 594.